Table 2.

Baseline and outcome data at follow-up in patients who participated in both follow-ups (n = 46).

	Before COVID-19 (n = 46)	4 months (n = 46)	12 months (n = 46)	p value (4 vs 12 months)
Time to follow-up (months)		4 (3.8–4.3)	12 (11.6–12.3)
BMI	29 (27–33)	30 (26–33)	32 (27–35)	<0.001
Place of residence:
Home	46 (100%)	44 (96%)	46 (100%)	0.157
Convalescent/rehabilitation home		2 (4%)
Occupational status:
Working full-time	29 (63%)	16 (35%)	17 (37%)	0.317
Working part-time	3 (6%)	4 (9%)	5 (11%)	0.317
Unemployed	0	1 (2%)	3 (6%)	0.157
Retired	11 (24%)	14 (30%)	15 (33%)	0.317
On sick leave	3 (6%)	11 (24%)	6 (13%)	0.025
Outcome				p value
modified Rankin Scale (mRS) (n = 46)		1 (1–2)	1 (1–2)	1.000
Post-COVID-19 Functional Status Scale (PCFS) (n = 46)		1 (1–2)	1 (1–3)	0.323
Clinical Frailty Scale (CFS) (n = 46)		2 (2–3)	3 (2–4)	0.002
EQ-5D-5L (n = 46)
Mobility		1.5 (1–2)	1 (1–2)	0.819
Self-Care		1 (1–1)	1 (1–1)	0.414
Usual Activity		2 (1–3)	2 (1–3)	0.201
Pain/discomfort		2 (1–3)	2 (1–3)	0.860
Anxiety/Depression		1.5 (1–2)	2 (1–2)	1.000
EQ-VAS		70 (59–85)	75 (50–85)	0.893
Montreal Cognitive Assessment (MoCa) (n = 42)		26 (24–28)	27 (26–29)	0.039
Multidimensional Fatigue Inventory (MFI 20)
General fatigue (n = 44)		14 (10–18)	14.5 (10–17)	0.796
Physical fatigue (n = 45)		14 (8–18)	14 (9–16)	0.539
Mental fatigue (n = 45)		10 (6–14)	9 (6–13)	0.084
Reduced motivation (n = 45)		9 (6–11)	8 (6–12)	0.974
Reduced activity (n = 45)		12 (8–17)	10 (8–15)	0.170
Generalised Anxiety Disorder 7-item scale (GAD-7) (n = 45)		2 (0–7)	2 (0–6)	0.112
Patient Depression Questionnaire 9 (PHQ-9) (n = 40)		4 (1–11)	3 (1–11)	0.211
6-minute walk test (6MWT) (n = 45)		522 (396–597)	525 (415–594)	0.802

Data are presented as number (percentage) or median with interquartile range (IQR).

Categorical data presented as number of total, n (percentage) and compared using Wilcoxon signed-rank test. Continuous data presented as median with interquartile range (IQR) and compared with Mann-Whitney U test.